The SA/UK ADD Hub's newly launched website!
Visit it now, here -->
https://t.co/bigKnOIqwV
Find out all about our Newton Fund AMR Project, the Consortium's news, upcoming events and more!
Made possible by @MRCza, @NewtonFund, @The_MRC
I’ve come to @thembauk on Plymouth Hoe for the launch of UK’s 1st Marine Microbiome Centre of Excellence! Imagine all the amazing microbiology to be discovered out there…we’re looking for new #antibiotics in #marinefungi with @sea_bugs@SA_UKADDHub
Sharing the WHO's Science in 5 Podcast. Take a moment to listen to what you need to know when taking #antibiotics 💊.
#antimicrobialstewardship
https://t.co/3p96vaHt9n
@NewtonFund It is most exciting that we get to do this research and collaborate with other passionate scientists in the field of #AMR and #NPdrugdiscovery!
‘I work in the field of natural products produced by fungi’
Introducing Dr Claudio Greco - his current research examines a pathogenic filamentous fungus that has co-evolved with leaf-cutter ants 🍄🐜
https://t.co/Er7qkd2psw
@BBSRC#bioscience#research#fungi
#DYK most cases of #Cdiff occur while you’re taking #antibiotics or not long after you’ve finished? Protect yourself and your loved ones from this life-threatening infection. https://t.co/z2MKVLYM4v #CdiffAwarenessMonth
New @WHO data shows that in 2021, #tuberculosis killed someone roughly every 20 seconds.
The number of people falling ill with TB and dying from it increased.
While the data is devastating, it is sadly unsurprising.
[1/7]
https://t.co/pZd3aTSky2
And so the 2022 #H3DSymposium comes to a close aftera hugely stimulating and inspiring conference! Thank you to all who made this opportunity possible to network and engage on the critical topics on #drugdiscovery in Africa, and further broad.
Overcoming infectious diseases is a complex and dynamic issue that require novel approaches, multiple approaches and out-of-the-box thinking to tackle #drugdiscovery in light of the #AMR global health issue.
Roi Avraham of @WeizmannScience considers the interaction between pathogens and host, using a Dynamic Deconvolution approach for single cell RNASeq to analysis the impact of human variation on cell-specific pathogen responses.
"Combination therapies is what we should aim for." Anna Hirsch's research tackles #drugdiscovery invesigating a Patholocker approach as adjunctive therapy to antibiotics for hospital-acquired P. aeruginosa infections.
#H3DSymposium
Rolf Miller opens the AMR #drugdiscovery session sharing his lab's work on identifying novel NPs from predatory myxobacteria of soil origin. He uses phylogenetically distant strains from those previously characterized to prioritize novel NP discovery.
#H3DSymposium
Following a jam-packed day of #drugdiscovery science, we celebrate the amazing research currently underway in Africa at the #H3DSymposium Conference Dinner with a delicious #proudlysouthafican spread.
Such an interesting and hugely topical discussion raised by @mathewnjoroge - how does genetic variation in African populations affect drug metabolism and deposition, and it's impact on development of resistance or drug toxicity.
"A good assay leads to good analysis, which supports good compound analogue design" for #drugdiscovery of XDR TB. Brendan Cowley @MERCK Sharp and Dohme, discusses improving the efficacy and selectivity of linezolid.
#H3DSymposium
Clif Barry of the @NIH challenges us to rethink our understanding of treating TB to sterility - is this achievable, particularly with our existing treatment regimens? This is an important consideration in the journey of #drugdiscovery for this critical infectious disease.
Clif Barry of the @NIH challenges us to rethink our understanding of treating TB to sterility - is this achievable, particularly with our existing treatment regimens? This is an important consideration in the journey of #drugdiscovery for this critical infectious disease.